688192 迪哲医药
已收盘 02-25 15:00:01
资讯
新帖
简况
迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%
证券之星 · 02-24 08:02
迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%
去年预亏7.7亿元，迪哲医药冲刺港股IPO
21世纪经济报道 · 01-28
去年预亏7.7亿元，迪哲医药冲刺港股IPO
营收爬坡、烧钱依旧，迪哲医药急赴港股再融资
市场资讯 · 01-25
营收爬坡、烧钱依旧，迪哲医药急赴港股再融资
新股消息 | 迪哲医药(688192.SH)递表港交所
智通财经 · 01-24
新股消息 | 迪哲医药(688192.SH)递表港交所
迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%
证券之星 · 01-21
迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%
迪哲医药：预计2025年净利润亏损7.7亿元左右
证券之星 · 01-12
迪哲医药：预计2025年净利润亏损7.7亿元左右
每周股票复盘：迪哲医药（688192）拟发行H股赴港上市
证券之星 · 01-11
每周股票复盘：迪哲医药（688192）拟发行H股赴港上市
迪哲医药（688192）披露拟发行H股并在港交所上市，1月9日股价上涨5.26%
证券之星 · 01-09
迪哲医药（688192）披露拟发行H股并在港交所上市，1月9日股价上涨5.26%
深化全球化布局 迪哲医药拟港股上市
市场资讯 · 01-07
深化全球化布局 迪哲医药拟港股上市
迪哲医药（688192）披露拟发行H股并在港交所上市，12月30日股价下跌3.27%
证券之星 · 2025-12-30
迪哲医药（688192）披露拟发行H股并在港交所上市，12月30日股价下跌3.27%
迪哲医药通过信息披露暂缓与豁免业务管理制度
中金财经 · 2025-12-25
迪哲医药通过信息披露暂缓与豁免业务管理制度
迪哲医药(688192.SH)筹划发行H股股票并在香港联交所上市
智通财经 · 2025-12-24
迪哲医药(688192.SH)筹划发行H股股票并在香港联交所上市
迪哲医药（688192）297.72万股限售股将于12月23日解禁，占总股本0.65%
证券之星 · 2025-12-23
迪哲医药（688192）297.72万股限售股将于12月23日解禁，占总股本0.65%
迪哲医药（688192）披露关于公司独立董事辞职的公告，12月18日股价下跌0.05%
证券之星 · 2025-12-18
迪哲医药（688192）披露关于公司独立董事辞职的公告，12月18日股价下跌0.05%
迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%
证券之星 · 2025-12-17
迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%
迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%
证券之星 · 2025-12-15
迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%
迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐
中金财经 · 2025-12-11
迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐
迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据
中金财经 · 2025-12-10
迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据
迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布
智通财经 · 2025-12-09
迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布
迪哲医药选举康晓静为职工董事
中金财经 · 2025-11-25
迪哲医药选举康晓静为职工董事
暂无数据
公司概况
公司名称：
迪哲(江苏)医药股份有限公司
所属行业：
医药制造业
上市日期：
2021-12-10
主营业务：
迪哲(江苏)医药股份有限公司的主营业务是恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲、Birelentinib、DZD6008。
发行价格：
52.58
{"stockData":{"symbol":"688192","market":"SH","secType":"STK","nameCN":"迪哲医药","latestPrice":52.51,"timestamp":1772002801000,"preClose":53.47,"halted":0,"volume":2826889,"delay":0,"changeRate":-0.018,"floatShares":461000000,"shares":465000000,"eps":-1.867,"marketStatus":"已收盘","change":-0.96,"latestTime":"02-25 15:00:01","open":53.2,"high":53.3,"low":50.85,"amount":147000000,"amplitude":0.0458,"askPrice":52.51,"askSize":36,"bidPrice":52.5,"bidSize":60,"shortable":0,"etf":0,"ttmEps":-1.867,"tradingStatus":0,"nextMarketStatus":{"tag":"开盘","tradingStatus":2,"beginTime":1772069400000},"marketStatusCode":5,"adr":0,"adjPreClose":53.47,"symbolType":"stock_kcb","openAndCloseTimeList":[[1771983000000,1771990200000],[1771995600000,1772002800000]],"highLimit":58.82,"lowLimit":48.12,"ibTradeSell":false,"ibTradeBuySell":true,"totalEquity":464633342,"isCdr":false,"pbRate":16.94,"roa":"--","roe":"--","epsLYR":-2.04,"committee":0.546326,"marketValue":24398000000,"turnoverRate":0.0061,"status":1,"afterMarket":{"amount":0,"volume":0,"close":52.51,"buyVolume":0,"sellVolume":0,"time":1772004837558,"indexStatus":"已收盘 02-25 15:30:00","preClose":53.47},"floatMarketCap":24190000000},"requestUrl":"/m/hq/s/688192/tweets","defaultTab":"tweets","newsList":[{"id":"2613567167","title":"迪哲医药（688192）99.11万股限售股将于2月24日解禁，占总股本0.21%","url":"https://stock-news.laohu8.com/highlight/detail?id=2613567167","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2613567167?lang=zh_cn&edition=full","pubTime":"2026-02-24 08:02","pubTimestamp":1771891349,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于2月24日将有99.11万股限售股份解禁，为公司股权激励期权行权，占公司总股本0.21%。最近一年内，该股累计解禁2.68亿股，占总股本的57.63%。本次解禁后，公司还有395.18万股限售股份，占总股本0.85%。迪哲医药主营业务：专注于恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026022400010438.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2606942777","title":"去年预亏7.7亿元，迪哲医药冲刺港股IPO","url":"https://stock-news.laohu8.com/highlight/detail?id=2606942777","media":"21世纪经济报道","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606942777?lang=zh_cn&edition=full","pubTime":"2026-01-28 17:56","pubTimestamp":1769594160,"startTime":"0","endTime":"0","summary":"21世纪经济报道记者 韩利明继益方生物（688382.SH）、泽璟制药（688266.SH）、信立泰（002294.SZ）、悦康药业（688658.SH）等本土药企在2025年底密集披露港股上市计划后，迪哲医药（688192. ...","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tonghuashun","url":"http://stock.10jqka.com.cn/20260128/c674373712.shtml","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://stock.10jqka.com.cn/20260128/c674373712.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tonghuashun","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2606726994","title":"营收爬坡、烧钱依旧，迪哲医药急赴港股再融资","url":"https://stock-news.laohu8.com/highlight/detail?id=2606726994","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2606726994?lang=zh_cn&edition=full","pubTime":"2026-01-25 18:39","pubTimestamp":1769337540,"startTime":"0","endTime":"0","summary":" 产品放量带来的减亏，并未改变资金的紧迫局面，迪哲医药将目光投向港交所。近日，迪哲医药正式向港交所递交上市申请，谋求港股上市。面对仍在持续的研发投入和常年亏损带来的历史缺口，迪哲医药的资金压力依旧高悬。此前A股募资已近枯竭，为维持多条核心管线的同步推进、避免在商业化冲刺前“失血”，赴港上市已成为支撑迪哲医药存活至盈利前的关键一役。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/jjxw/2026-01-25/doc-inhipmct8978957.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["162717","688192"],"gpt_icon":0},{"id":"2605872235","title":"新股消息 | 迪哲医药(688192.SH)递表港交所","url":"https://stock-news.laohu8.com/highlight/detail?id=2605872235","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605872235?lang=zh_cn&edition=full","pubTime":"2026-01-24 17:39","pubTimestamp":1769247557,"startTime":"0","endTime":"0","summary":"智通财经APP获悉，据港交所1月23日披露，迪哲(江苏)医药股份有限公司(简称：迪哲医药(688192.SH))向港交所主板递交上市申请书，高盛和华泰国际为其联席保荐人。据招股书，迪哲医药是一家处于商业化阶段的生物制药公司，公司的核心治疗领域是肿瘤及血液系统疾病。公司的上市产品舒沃哲®是全球范围内唯一获批用于治疗EGFR 20号外显子插入突变型肺癌的小分子表皮生长因子受体酪氨酸激酶抑制剂。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1396984.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["HEXmain","BK0239","688192"],"gpt_icon":0},{"id":"2605483414","title":"迪哲医药（688192）披露关于变更公司英文名称、修订《公司章程》并办理工商变更登记的公告，1月21日股价下跌1.48%","url":"https://stock-news.laohu8.com/highlight/detail?id=2605483414","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2605483414?lang=zh_cn&edition=full","pubTime":"2026-01-21 22:30","pubTimestamp":1769005838,"startTime":"0","endTime":"0","summary":"截至2026年1月21日收盘，迪哲医药报收于61.79元，较前一交易日下跌1.48%，最新总市值为286.72亿元。近日，迪哲（江苏）医药股份有限公司召开第二届董事会第十九次会议，审议通过了《关于变更公司英文名称、修订〈公司章程〉并办理工商变更登记的议案》。董事会已授权公司管理层办理相关工商变更、登记及备案事宜。本次修订仅涉及公司英文名称变更，其他条款保持不变，最终以市场监督管理部门登记备案为准。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026012100041104.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2602515147","title":"迪哲医药：预计2025年净利润亏损7.7亿元左右","url":"https://stock-news.laohu8.com/highlight/detail?id=2602515147","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602515147?lang=zh_cn&edition=full","pubTime":"2026-01-12 18:20","pubTimestamp":1768213246,"startTime":"0","endTime":"0","summary":"迪哲医药(688192.SH)公告称，迪哲医药发布2025年度业绩预告，预计归属于母公司所有者的净亏损7.7亿元左右，较上年同期减少亏损约7,596万元。报告期内，公司两款获批产品舒沃哲和高瑞哲纳入国家医保药品目录，推动产品销售收入增长至约8亿元，同比增长122.28%。以上内容为证券之星据公开信息整理，由AI算法生成（网信算备310104345710301240019号），不构成投资建议。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011200026699.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192"],"gpt_icon":0},{"id":"2602535300","title":"每周股票复盘：迪哲医药（688192）拟发行H股赴港上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2602535300","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602535300?lang=zh_cn&edition=full","pubTime":"2026-01-11 02:36","pubTimestamp":1768070169,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，迪哲医药报收于66.79元，较上周的57.6元上涨15.95%。本周，迪哲医药1月9日盘中最高价报67.08元。1月5日盘中最低价报56.52元。迪哲医药当前最新总市值308.03亿元，在化学制药板块市值排名14/150，在两市A股市值排名681/5182。所有议案均获通过，无被否决议案。北京市中伦律师事务所对本次股东会进行见证并出具法律意见书，确认会议的召集、召开程序、出席人员资格、表决程序及表决结果合法有效。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026011100000641.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2602743963","title":"迪哲医药（688192）披露拟发行H股并在港交所上市，1月9日股价上涨5.26%","url":"https://stock-news.laohu8.com/highlight/detail?id=2602743963","media":"证券之星","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2602743963?lang=zh_cn&edition=full","pubTime":"2026-01-09 22:22","pubTimestamp":1767968539,"startTime":"0","endTime":"0","summary":"截至2026年1月9日收盘，迪哲医药报收于66.79元，较前一交易日上涨5.26%，最新总市值为308.03亿元。根据近日发布的公告，迪哲（江苏）医药股份有限公司于2026年1月9日召开第一次临时股东会，审议通过了关于发行H股股票并在香港联合交易所上市的相关议案。会议内容包括H股上市方案、募集资金使用计划、决议有效期、授权董事会处理相关事宜、修订公司章程（草案）及相关议事规则（草案）、H股发行前滚存利润分配方案以及聘请审计机构等事项。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2026010900040907.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["HEXmain","BK0239","688192"],"gpt_icon":0},{"id":"2601840448","title":"深化全球化布局 迪哲医药拟港股上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2601840448","media":"市场资讯","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2601840448?lang=zh_cn&edition=full","pubTime":"2026-01-07 07:58","pubTimestamp":1767743880,"startTime":"0","endTime":"0","summary":" 迪哲（江苏）医药股份有限公司近日公告，为深化全球化战略布局，提升公司国际化品牌形象，拟发行境外上市外资股（H股）股票并在港交所挂牌上市。 作为由阿斯利康亚洲研发中心独立出来的创新药企，迪哲医药成立于2017年，专注于恶性肿瘤、免疫性疾病领域，2021年在科创板挂牌上市。 自2023年首款商业化产品舒沃哲获批上市后，迪哲医药逐步实现研发成果的市场价值转化。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hyyj/2026-01-07/doc-inhfmycx7652979.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2595553713","title":"迪哲医药（688192）披露拟发行H股并在港交所上市，12月30日股价下跌3.27%","url":"https://stock-news.laohu8.com/highlight/detail?id=2595553713","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2595553713?lang=zh_cn&edition=full","pubTime":"2025-12-30 22:40","pubTimestamp":1767105639,"startTime":"0","endTime":"0","summary":"截至2025年12月30日收盘，迪哲医药报收于56.15元，较前一交易日下跌3.27%，最新总市值为258.96亿元。该股当日开盘57.58元，最高58.24元，最低55.9元，成交额达1.79亿元，换手率为0.7%。近日，迪哲医药发布《2026年第一次临时股东会会议资料》公告，宣布公司拟发行境外上市外资股（H股）并在香港联合交易所主板挂牌上市，旨在深化全球化战略布局，提升公司核心竞争力。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025123000044581.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192","HEXmain"],"gpt_icon":0},{"id":"2594303283","title":"迪哲医药通过信息披露暂缓与豁免业务管理制度","url":"https://stock-news.laohu8.com/highlight/detail?id=2594303283","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2594303283?lang=zh_cn&edition=full","pubTime":"2025-12-25 08:23","pubTimestamp":1766622196,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司为规范其信息披露暂缓与豁免行为，依据相关法律法规及公司章程，制定了《信息披露暂缓与豁免业务管理制度(草案)》。 根据制度规定，迪哲医药在特定情况下可对拟披露信息进行暂缓或豁免处理。该制度自公司H股在香港联交所挂牌上市之日起施行，标志着迪哲医药在完善信息披露内控体系、平衡信息披露与商业保密需求方面迈出重要一步。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251225/31891071.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2593473981","title":"迪哲医药(688192.SH)筹划发行H股股票并在香港联交所上市","url":"https://stock-news.laohu8.com/highlight/detail?id=2593473981","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593473981?lang=zh_cn&edition=full","pubTime":"2025-12-24 17:22","pubTimestamp":1766568175,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药(688192.SH)发布公告，为深化全球化战略布局，提升公司国际化品牌形象，进一步提升公司核心竞争力，公司拟发行境外上市外资股(简称“H股”)股票并在香港联合交易所有限公司(简称“香港联交所”)主板挂牌上市。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1385513.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2593459083","title":"迪哲医药（688192）297.72万股限售股将于12月23日解禁，占总股本0.65%","url":"https://stock-news.laohu8.com/highlight/detail?id=2593459083","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2593459083?lang=zh_cn&edition=full","pubTime":"2025-12-23 08:12","pubTimestamp":1766448726,"startTime":"0","endTime":"0","summary":"证券之星消息，根据市场公开信息整理，迪哲医药于12月23日将有297.72万股限售股份解禁，为公司股权激励期权行权，占公司总股本0.65%。最近一年内，该股累计解禁3.28亿股，占总股本的71.21%。本次解禁后，公司还有494.28万股限售股份，占总股本1.07%。迪哲医药主营业务：创新药的研发。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025122300005605.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2592902248","title":"迪哲医药（688192）披露关于公司独立董事辞职的公告，12月18日股价下跌0.05%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592902248","media":"证券之星","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592902248?lang=zh_cn&edition=full","pubTime":"2025-12-18 22:47","pubTimestamp":1766069240,"startTime":"0","endTime":"0","summary":"截至2025年12月18日收盘，迪哲医药报收于57.47元，较前一交易日下跌0.05%，最新总市值为265.04亿元。该股当日开盘57.67元，最高57.98元，最低57.2元，成交额达5210.96万元，换手率为0.2%。因个人工作原因，王学恭先生申请辞去公司独立董事及董事会各专门委员会相关职务。辞职将在公司股东大会选举产生新任独立董事后生效。在改选期间，王学恭先生将继续履行职责。截至公告披露日，王学恭先生未持有公司股份。公司董事会对其任职期间的贡献表示感谢。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121800039355.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2592916301","title":"迪哲医药（688192）披露2022年限制性股票激励计划部分限制性股票符合归属条件，12月17日股价上涨0.86%","url":"https://stock-news.laohu8.com/highlight/detail?id=2592916301","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2592916301?lang=zh_cn&edition=full","pubTime":"2025-12-17 22:37","pubTimestamp":1765982244,"startTime":"0","endTime":"0","summary":"截至2025年12月17日收盘，迪哲医药报收于57.5元，较前一交易日上涨0.86%，最新总市值为265.18亿元。近日，迪哲医药发布关于2022年限制性股票激励计划首次授予及预留授予部分限制性股票符合归属条件的公告。公告显示，公司于2025年12月16日召开董事会，审议通过相关议案，确认2022年限制性股票激励计划中首次授予的第一类激励对象第三个归属期、第二类激励对象第二个归属期以及预留授予激励对象第一个归属期的归属条件均已达成。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121700040200.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2591642135","title":"迪哲医药（688192）披露2020年员工股份期权计划第二个行权期第一次行权限售股上市流通公告，12月15日股价下跌5.73%","url":"https://stock-news.laohu8.com/highlight/detail?id=2591642135","media":"证券之星","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2591642135?lang=zh_cn&edition=full","pubTime":"2025-12-15 22:34","pubTimestamp":1765809251,"startTime":"0","endTime":"0","summary":"截至2025年12月15日收盘，迪哲医药报收于58.54元，较前一交易日下跌5.73%，最新总市值为269.98亿元。该股当日开盘61.52元，最高61.62元，最低58.54元，成交额达1.98亿元，换手率为0.73%。公司近日发布公告，披露关于2020年员工股份期权计划第二个行权期第一次行权限售股上市流通的相关情况。该部分股份于2022年12月23日完成登记，限售期为36个月，上市流通日期为2025年12月23日。保荐机构华泰联合证券对本次限售股上市流通无异议。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://stock.stockstar.com/RB2025121500036194.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stockstar","symbols":["BK0239","688192"],"gpt_icon":0},{"id":"2590466593","title":"迪哲医药连亏6年3季度 A股募38.99亿IPO中信证券保荐","url":"https://stock-news.laohu8.com/highlight/detail?id=2590466593","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590466593?lang=zh_cn&edition=full","pubTime":"2025-12-11 16:07","pubTimestamp":1765440426,"startTime":"0","endTime":"0","summary":"中国经济网北京12月11日讯 迪哲医药 近日发布2025年第三季度报告显示，2025年第三季度，公司实现营业收入2.31亿元，同比增长71.46%；归属于上市公司股东的净利润-2.03亿元；归属于上市公司股东的扣除非经常性损益的净利润-2.11亿元。 迪哲医药首次公开发行股票募集资金总额为21.03亿元，扣除发行费用后募集资金净额为19.87亿元。 迪哲医药2次募资合计募集资金38.99亿元。","market":"hk","thumbnail":" http://caiji.3g.cnfol.com/colect/202512/11/20251211208540.png","type":0,"news_type":0,"thumbnails":[" http://caiji.3g.cnfol.com/colect/202512/11/20251211208540.png"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20251211/31859232.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK0012","LU1064131003.USD","399300","LU1064130708.USD","LU1255011170.USD","LU1720050803.USD","06030","LU0405327148.USD","LU1997245177.USD","600030","LU1794554557.SGD","688192","LU1328615791.USD","BK0239","BK1521","BK1147","LU2148510915.USD","LU1655091616.SGD","LU2289578879.USD","BK1516","BK0276","BK0028","BK1564","BK0188","BK0183","LU1997245094.SGD","BK0196","LU1997244956.HKD","159982","LU0405327494.USD","LU2495084118.USD"],"gpt_icon":0},{"id":"2590583770","title":"迪哲医药ASH大会发布高瑞哲®与Birelentinib淋巴瘤治疗最新积极数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2590583770","media":"中金财经","labels":[],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590583770?lang=zh_cn&edition=full","pubTime":"2025-12-10 17:56","pubTimestamp":1765360604,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司在第67届美国临床血液学会年会上，公布了其两款全球首创新药在淋巴瘤治疗领域的最新临床研究进展。另一方面，其非共价LYN/BTK双靶点抑制剂Birelentinib在B细胞淋巴瘤领域取得新进展。公司同时披露了Birelentinib联合疗法治疗弥漫性大B细胞淋巴瘤的后续研究计划。这些数据进一步验证了迪哲医药两款核心产品的临床价值，为其在淋巴瘤治疗领域的商业化前景提供了支持。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251210/31856740.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["ASH","688192","BK0239","LU2463526074.USD","BK4109"],"gpt_icon":0},{"id":"2590131413","title":"迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布","url":"https://stock-news.laohu8.com/highlight/detail?id=2590131413","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2590131413?lang=zh_cn&edition=full","pubTime":"2025-12-09 15:43","pubTimestamp":1765266190,"startTime":"0","endTime":"0","summary":"智通财经APP讯，迪哲医药 公告，公司第67届美国临床血液学会大会上，公布了公司自主研发的两款全球首创新药的最新研究成果：高选择性JAK1抑制剂高瑞哲在T细胞淋巴瘤领域取得多项新进展，以及非共价LYN/BTK双靶点抑制剂birelentinib在B细胞淋巴瘤治疗领域的最新临床数据。本次ASH大会，迪哲公布了该研究的最新随访数据。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1379270.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"迪哲医药(688192.SH)：高瑞哲和Birelentinib最新研究数据在第67届美国临床血液学会发布","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["688192","BK0239"],"gpt_icon":0},{"id":"2586469554","title":"迪哲医药选举康晓静为职工董事","url":"https://stock-news.laohu8.com/highlight/detail?id=2586469554","media":"中金财经","labels":["executive"],"top":-1,"itemType":null,"share":"https://www.laohu8.com/m/news/2586469554?lang=zh_cn&edition=full","pubTime":"2025-11-25 13:04","pubTimestamp":1764047048,"startTime":"0","endTime":"0","summary":"中访网数据 迪哲(江苏)医药股份有限公司于2025年11月21日召开职工代表大会，选举康晓静女士为公司职工董事。此次会议以电子通信方式举行，共有105名职工代表出席，符合法定人数。根据会议决议，康晓静女士的任期自决议通过之日起至公司第二届董事会任期届满之日止。公告显示，康晓静女士现任公司财务主管，持有公司股票17,000股，其任职资格符合《公司法》及《公司章程》的相关规定。此次选举完成后，公司董事会中兼任高级管理人员及由职工代表担任的董事总数未超过董事总数的二分之一，符合监管要求。这一人事变动是公司完善治理结构的一部分，旨在保障职工参与企业民主管理的权利。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/ggzixun/20251125/31821755.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["688192","BK0239"],"gpt_icon":0}],"profile":{"ret":0,"serverTime":1772047660101,"stockEarnings":[{"period":"1week","weight":-0.0249},{"period":"1month","weight":-0.1038},{"period":"3month","weight":-0.1935},{"period":"6month","weight":-0.3157},{"period":"1year","weight":0.1256},{"period":"ytd","weight":-0.0884}],"compareEarnings":[{"period":"1week","weight":0.016},{"period":"1month","weight":0.0035},{"period":"3month","weight":0.0702},{"period":"6month","weight":0.075},{"period":"1year","weight":0.2394},{"period":"ytd","weight":0.0449}],"compareStock":{"symbol":"000001.SH","name":"上证指数"},"companyName":"迪哲(江苏)医药股份有限公司","boardCode":"AI0027","boardName":"医药制造业","stockholders":"8806人(较上一季度增加5.01%)","perCapita":"52314股","listingDate":"2021-12-10","address":"江苏省无锡市新吴区和风路26号汇融商务广场C栋404、405、416室","registeredCapital":"46463万元","survey":" 迪哲(江苏)医药股份有限公司的主营业务是恶性肿瘤、免疫性疾病领域创新疗法的研究、开发和商业化。公司的主要产品是舒沃哲、高瑞哲、Birelentinib、DZD6008。","listedPrice":52.58},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"tenantId":"TBCN","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","keywords":"迪哲医药,688192,迪哲医药股票,迪哲医药股票老虎,迪哲医药股票老虎国际,迪哲医药行情,迪哲医药股票行情,迪哲医药股价,迪哲医药股市,迪哲医药股票价格,迪哲医药股票交易,迪哲医药股票购买,迪哲医药股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"迪哲医药(688192)_个股概要_股票价格_最新资讯_行情走势_历史数据","og_description":"美港股上老虎。老虎社区提供迪哲医药(688192)今日价格,行情走势,历史数据,股票概要及实时的新闻资讯,近期大事等重要参考决策数据。","og_image":"https://static.tigerbbs.com/a0b84b8debbbce3b4440f7fdd5eed2e7"}}}